Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS One, 2016, 11, (7), e0158779, 1-19. Doi : 10.1371/journal.pone.0158779 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharma- cological assays, including mice tests for anxiety, obsessive-compulsive disorder, depres- sion and schizophrenia. In human [...]
Lire la suiteThe Impact of Cannabidiol on Human Brain Function : A Systematic Review, Albert Batalla et al., 2021
The Impact of Cannabidiol on Human Brain Function : A Systematic Review Albert Batalla, Julian Bos, Amber Postma and Matthijs G. Bossong Frontiers in Pharmacology, January 2021 | Volume 11 | Article 618184, 1-15. doi : 10.3389/fphar.2020.618184 Background : Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies [...]
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....) 1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]
Lire la suiteCannabis and cannabinoid use in autism spectrum disorder : a systematic review Estácio Amaro da Silva Junior, Wandersonia Moreira Brito Medeiros, Nelson Torro, João Marçal Medeiros de Sousa, Igor Bronzeado Cahino Moura de Almeida, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Eliane Lima Guerra Nunes, Marine Diniz da Rosa, Katy Lísias Gondim Dias de Albuquerque Trends in Psychiatry and Psychotherapy, 2021, 1-10. Doi : 10.47626/2237-6089-2020-0149 Abstract Introduction : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction, associated with the presence of restricted and repetitive patterns of behavior, interests, or activities. Cannabis has been used to alleviate [...]
Lire la suiteAltered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004 Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteCannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042 Highlights Cannabidiol (CBD) attenuated haloperidol-induced catalepsy. CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol. CBD effects were blocked by 5-HT1A receptor antagonist. Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]
Lire la suiteCannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats Ewa Kozela & Martyna Krawczyk & Tomasz Kos & Ana Juknat & Zvi Vogel & Piotr Popik Molecular Neurobiology, 2019, Doi : 10.1007/s12035-019-01831-2 Abstract Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. The mechanisms of these beneficial effects of CBD are unknown. Here, we examined behavioral effects of CBD in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine (KET) administration. In parallel, we assessed transcriptional changes behind CBD activities in the prefrontal cortex (PFC), the [...]
Lire la suiteA tale of two cannabinoids : The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Ethan Russo & Geoffrey W. Guy Medical Hypotheses, 2006, 66, 234–246 doi : 10.1016/j.mehy.2005.08.026 Summary This study examines the current knowledge of physiological and clinical effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) and presents a rationale for their combination in pharmaceutical preparations. Cannabinoid and vanilloid receptor effects as well as non-receptor mechanisms are explored, such as the capability of THC and CBD to act as anti-inflammatory substances independent of cyclo-oxygenase (COX) inhibition. CBD is demonstrated to antagonise some undesirable effects of THC including intoxication, sedation and tachycardia, while contributing analgesic, anti-emetic, [...]
Lire la suiteA behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Leonora E. Long, Rose Chesworth, Xu-Feng Huang, Iain S. McGregor, Jonathon C. Arnold and Tim Karl International Journal of Neuropsychopharmacology, 2010, 13, 861–876. doi : 10.1017/S1461145709990605 Abstract Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent D9 tetrahydro-cannabinol (D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia. Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, [...]
Lire la suite